Potent endogenous cannabinoid and vanilloid receptor agonist, with no action at dopamine receptors. Selective for CB1 over CB2 receptors (Ki values are 0.25 and 12 μM respectively), and potent agonist at TRPV1 (VR1) receptors (EC50 ~ 50 nM). Metabolically stable and competitively inhibits FAAH and anandamide transport. Has cannabinoid and vanilloid actions in vivo.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble in ethanol (supplied pre-dissolved in anhydrous ethanol, 5mg/ml)|
Preparing Stock Solutions
The following data is based on the product molecular weight 439.64. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.27 mL||11.37 mL||22.75 mL|
|5 mM||0.45 mL||2.27 mL||4.55 mL|
|10 mM||0.23 mL||1.14 mL||2.27 mL|
|50 mM||0.05 mL||0.23 mL||0.45 mL|
References are publications that support the products' biological activity.
Bisogno et al (2000) N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem.J. 351 817 PMID: 11042139
De Petrocellis et al (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483 52 PMID: 11033355
Huang et al (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc.Natl.Acad.Sci.U.S.A. 99 8400 PMID: 12060783
If you know of a relevant reference for NADA, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: NADA, supplier, Endogenous, CB1, agonists, vanilloid, inhibitors, inhibits, FAAH, AMT, TRPV1, cannabinoids, Receptors, Vanillioids, VR1, Channels, Transient, Receptor, Potential, cb1r, N-Arachidonyldopamine, AA-DA, CB1, Receptors, TRPV, CB1, Receptors, Tocris Bioscience
2 Citations for NADA
Citations are publications that use Tocris products. Selected citations for NADA include:
Pitcher et al (2007) Spinal NKCC1 blockade inhibits TRPV1-dependent referred allodynia. J Pharmacol Exp Ther 3 17 PMID: 17603899
Kaszás et al (2012) Small molecule positive allosteric modulation of TRPV1 activation by vanilloids and acidic pH. PLoS One 340 152 PMID: 22005042
Do you know of a great paper that uses NADA from Tocris? If so please let us know.
Reviews for NADA
There are currently no reviews for this product. Be the first to review NADA and earn rewards!
Have you used NADA?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.